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Introduction
Throughout recent years, asthma and
chronic obstructive pulmonary disease
(COPD) have been viewed as two
separate diseases, with two separate
pathophysiologies, and two different
treatment plans, essentially ignoring the
possibility of a dual diagnosis.
(Barrecheguren, Esquinas, & Mirvitlles,
2015). In 2014 the Global Initiative for
Chronic Lung Disease (GOLD) and Global
Initiative for Asthma (GINA)
acknowledged that patients could
indeed have both pathophysiologies of
COPD and asthma (GOLD & GINA, 2015).
The GOLD and GINA collaboration led to
a consensus description of what is
referred to as the asthma-COPD overlap
syndrome (ACOS) (GOLD & GINA, 2015).
Asthma is defined as a heterogeneous
disease, usually characterized by chronic
airway inflammation (GOLD & GINA,
2015). It is defined by the history of
respiratory symptoms such as wheeze,
shortness of breath, chest tightness and
cough that vary over time and in
intensity, together with variable
expiratory airflow limitation (GINA,
2017). COPD is defined as a common
preventable and treatable disease,
characterized by persistent airflow
limitation that is usually progressive and
associated with enhanced chronic
inflammatory responses in the airways
and the lungs to noxious particles or
gases (GOLD, 2017). ACOS is
characterized by persistent airflow
limitation with several features usually
associated with asthma and several
features usually associated with COPD
(GOLD & GINA, 2015).
The prevalence of ACOS in patients
diagnosed with COPD is approximately
20% and unfortunately is characterized
by more frequent exacerbations
(Karampitsakos & Gourgoulianis, 2016).
Patients with ACOS are typically younger
with higher comorbidities, disabilities,
hospitalizations, and ED visitations
compared to COPD alone. (Kumbhare,
Pleasants, Ohar, & Strange, 2016). If the
clinician does not take the time to
correctly identify the disease behind the
respiratory traits, the patient may be
missing appropriate treatments, which
could lead to more frequent
exacerbations.

Underlying Pathophysiology

Significance of Pathophysiology

ACOS pathophysiology is speculative and contains several different clinical phenotypes and several
different mechanisms (GINA, 2017). ACOS involves inflammatory processes that lead to respiratory
remodeling, reactive airways, tissue damage and lung hyperinflation. The inflammatory processes include
the asthma-like eosinophilic inflammation, yet the COPD-like neutrophilic sputum production may be
present (Sin, 2017). A type 2 (T2) helper cell inflammatory pathway seen in asthma has been found in
some COPD patients, which brings speculation that these are actually ACOS patients (Sin, 2017). A
proinflammatory proteolytic cascade leads to lung tissue breakdown and mild centrilobular emphysema
not easily detectable by lung CAT scans, and not a true feature of stand-alone asthma, yet seen in ACOS
patients (Gelb, Yamamoto, Verbeken, & Nadel, 2015). Additionally, ACOS patients show less emphysema
burden than pure COPD patients (Sin, 2017). These latter mentioned changes cause a loss of lung elastic
recoil and therefore hyperinflation of the lungs (Gelb, Yamamoto, Verbeken, & Nadel, 2015).

Inflammation in asthma is affiliated with increases in CD4+ T-lymphocytes and
eosinophils. Inflammation in COPD is characterized by increases in CD8+ Tlymphocytes, neutrophils, and macrophages (Wurst, Kelly-Reif, Bushnell, Pascoe,
& Barnes, 2016). Treatments for the two diseases are dictated by the underlying
pathophysiologies. ACOS, having a mixture of the two, has a unique
pharmacotherapy that requires early use of inhaled corticosteroids, which are
not typically used in COPD until later in disease progression in stage D (GOLD,
2017).

Figure 1. Hypothetical course of lung function in chronic obstructive pulmonary disease (COPD) and
asthma (Postma & Rabe, 2015).

Signs and Symptoms
Signs and symptoms of ACOS involve signs and symptoms of both asthma and COPD:
Asthma signs and symptoms include:
•
Variable expiratory airflow
•
Wheezing
•
Shortness of breath
•
Chest tightness
•
Cough
•
due to bronchoconstriction, airway
wall thickening, and increased
mucus (GINA, 2017).
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COPD signs and symptoms include:
•
Dyspnea progressive over time, worse
with exercise and persistent.
•
Chronic cough w or w/o sputum
•
Recurrent wheeze
•
Lower respiratory tract infections
•
History of exposure to smoke, dusts,
vapors, fumes, or gases.
•
Family history of COPD and/or childhood
factors (GOLD, 2017).

Using the signs and symptoms of asthma and COPD, assemble the features that, when present, most
favour a diagnosis of typical asthma or typical COPD.
Compare the number of features on each side.
If the patient has ≥3 features of either asthma or COPD, there is a strong likelihood that this is the
correct diagnosis.
When a patient has a similar number of features of both asthma and COPD, consider the diagnosis
of asthma-COPD overlap (GINA, 2017).

Stepwise Approach to Care
Table 1. Stepwise Approach to Care (GINA, 2017).

Implications for Nursing
Care
Patients with ACOS often are not given
appropriate treatment because ACOS patients
are being diagnosed either with COPD or with
asthma, leaving part of their underlying
disease process untreated (Postma & Klaus,
2015). Because the majority of patients with
COPD are diagnosed in the primary care
setting, the primary care nurse practitioner
(NP) will need to have awareness of ACOS
characteristics and a willingness to screen for
airway disease in at-risk patients. The primary
care NP must ensure proper training for the
staff members on calibration of the office
based spirometry equipment, and ensure the
staff members administering the spirometry
testing have proper patient testing technique.
With the ACOS being a new diagnosis based on
features of two other diseases, it may seem to
be easier for the NP to simply “treat the traits”
of the disease. Caution is advised against
treating the traits, and instead to discern the
underlying disease process because ACOS
usually has co-morbidities, and treating the
traits can lead to polypharmacy (Sin, 2017).
Because ACOS patients report a higher
burden of self care and have a higher
hospitalization rate, nursing care will have to
include assuring the ACOS patient receives
timely access to follow up care, assuring the
patient has transportation to the appointment,
the ability to access medications, has
medication device training , and medication
reconciliation at each visit (Kumbhare,
Pleasants, Ohar, & Strange, 2016).
Consideration should be given to the need for
homecare nursing visitation to assess the
home environment for possible triggers,
provide additional medication device training,
assess the social support system, and
functional abilities in the home.

Conclusion
COPD and asthma are prevalent worldwide
diseases. ACOS, the disease that combines
characteristics of these diseases, is no longer
being ignored. ACOS is a difficult disease to
diagnose and comes with a high health care
economic cost to society. Understanding and
management of ACOS will improve as the
disease is increasingly studied. Patient
education for self management to improve
outcomes and avoid hospitalization will
become a large part of the nurse’s
responsibilities when caring for the ACOS
patient.
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